Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seagen Inc.
With
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of multiple myeloma.
Received at least one prior systemic therapy other than single-agent corticosteroids.
Measurable disease of monoclonal protein greater than or equal to 0.5 gram/dL in plasma or 0.5 gram/24 hr urine collection, or greater than 10 mg/dL free light chain (FLC) in serum as determined by serum FLC assay and provided the serum FLC ratio is abnormal.
You may not be if
Received an allogenic stem cell transplant.
Previous intolerance of lenalidomide or dexamethasone.
Primary invasive malignancy (other than multiple myeloma) within the last 3 years.
Clareo Health | Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
